Company Overview and News

0
Mod in $27m copper deal

2018-07-18 businessnews.com.au
MOD Resources has moved to full ownership of its T3 copper project in Botswana, after acquiring LSX-listed Metal Tiger’s stake of the project in a scrip deal worth $26.6 million.
MOD

0
MOD Resources to take its ownership of T3 Copper Project to 100%

2018-07-18 proactiveinvestors.com.au
MOD Resources Ltd (ASX:MOD) has executed binding agreements to acquire JV partner Metal Tiger’s (AIM:MTR) 30% share of the T3 Copper Project in Botswana.
MTR MOD

0
MOD Resources increases T3 indicated copper resource by 13%, drill testing additional potential extensions

2018-07-16 proactiveinvestors.com.au
MOD Resources Ltd (ASX:MOD) has increased the indicated mineral resource of its T3 Copper-Silver Project in Botswana by 13%, based on a reclassification review by CSA Global.
MTR MOD

0
MOD Resources observes strong visible copper at depth within A4 Dome at T3

2018-07-09 proactiveinvestors.com.au
MOD Resources Ltd (ASX:MOD) has intersected strong visible copper mineralisation in drilling at depth at the A4 Dome within the T3 Copper-Silver Project in Botswana.
MTR MOD

0
MOD Resources increases T3 copper resource by 44%

2018-07-02 proactiveinvestors.com.au
MOD Resources Ltd (ASX:MOD) has increased the total mineral resource at its T3 project in Botswana to 60 million tonnes at 0.98% copper and 14 g/t silver.
MOD

0
MOD Resources (MDRUF) Presents At 121 Mining Investment Conference - Slideshow

2018-05-18 seekingalpha
The following slide deck was published by MOD RESOURCES LIMITED ORD in conjunction with this event.
MOD

0
MOD Resources extremely undervalued say analysts based on pre-feasibility study

2018-04-03 proactiveinvestors.com.au
MOD Resources Ltd’s (ASX:MOD) environmental management plan has been approved, paving the way for drilling at its T3 copper deposit in Botswana.
MTR MOD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MOD / MOD RESOURCES LIMITED on message board site Silicon Investor.

Politics for Pros- moderated Immunomedics (IMMU) - moderated
Microsoft Corp. - Moderated (MSFT) Qualcomm Moderated Thread - please read rules before posting
The Residential Real Estate Post-Crash Index-Moderated NFLX Moderated Thread
True face of China -- A Modern Kaleidoscope The Enron Scandal - Unmoderated
Apple, Inc. Unmoderated Nigerian Scam Baiting - Letu0027s Discuss the Modalities